Quintet Private Bank Europe S.A. Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Quintet Private Bank Europe S.A. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 16.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,403 shares of the life sciences company’s stock after buying an additional 194 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Illumina were worth $183,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ILMN. Versant Capital Management Inc lifted its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina in the 2nd quarter worth about $34,000. Massmutual Trust Co. FSB ADV grew its stake in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in Illumina in the 2nd quarter worth about $61,000. Finally, Mizuho Securities Co. Ltd. bought a new position in Illumina in the 2nd quarter worth about $63,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Robert W. Baird upped their target price on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. TD Cowen upgraded shares of Illumina from a “hold” rating to a “buy” rating and increased their price objective for the company from $126.00 to $144.00 in a research note on Wednesday, August 14th. Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the company from $120.00 to $154.00 in a research note on Friday, August 16th. Piper Sandler dropped their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Finally, UBS Group increased their price objective on shares of Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $155.50.

Illumina Trading Up 2.5 %

Shares of ILMN stock opened at $153.49 on Tuesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The company has a 50 day moving average price of $136.39 and a 200 day moving average price of $122.65. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $155.37.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the business posted $0.32 EPS. The firm’s revenue was down 5.4% on a year-over-year basis. Sell-side analysts forecast that Illumina, Inc. will post 3.62 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.